AbstractBACKGROUND: Improved treatment have modified survival outcome in patients with diffuse large B-cell lymphoma (DLBCL) and altered the importance of previously recognized prognostic markers. Design and methods: To evaluate International Prognostic Index (IPI) score before and after rituximab introduction and to validate the absolute lymphocyte count (ALC)/revised International Prognostic Index (R-IPI) model, we carried out a retrospective analysis on a total of 831 patients with DLBCL. RESULTS: Our results show that IPI lost its discriminating power with the introduction of rituximab. The analysis of our second set allowed us to validate the ALC/R-IPI model. The R-IPI and ALC/R-IPI could still be used for designing clinical trials, but both have difficulty recognizing a high percentage of poor prognosis patients, though it remains an important goal of a good prognostic model considering the modest impact of salvage treatments on survival. CONCLUSIONS: A new model on the basis of significant variables in the rituximab era and built on a large database of patients treated with rituximab is urgently needed. As prognostic models are changing with the efficacy and mechanisms of action of treatment utilized, looking for a new prognostic score is a never-ending story in which researchers are trying to hit a continuously moving target.
|Data di pubblicazione:||2009|
|Titolo:||Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.|
|Autore/i:||Bari A; Marcheselli L; Sacchi S; Marcheselli R; Pozzi S; Ferri P; Balleari E; Musto P; Neri S; Aloe Spiriti MA; Cox MC.Department of Oncology and Hematology; University of Modena and Reggio Emilia; Modena.|
|Codice identificativo Scopus:||2-s2.0-77954261226|
|Citazione:||Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. / Bari A; Marcheselli L; Sacchi S; Marcheselli R; Pozzi S; Ferri P; Balleari E; Musto P; Neri S; Aloe Spiriti MA; Cox MC.Department of Oncology and Hematology; University of Modena and Reggio Emilia; Modena.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 17(2009), pp. 0-10.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris